| Allison Weiss Langowski, AGPCNP-BC | |
|
223 N Van Dien Ave, Ridgewood, NJ 07450-2736 | |
| (201) 447-8000 | |
| Not Available |
| Full Name | Allison Weiss Langowski |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Location | 223 N Van Dien Ave, Ridgewood, New Jersey |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154738540 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363L00000X | Nurse Practitioner | 306967 (New York) | Secondary |
| 363L00000X | Nurse Practitioner | 26NJ00964400 (New Jersey) | Primary |
| Entity Name | Icahn School Of Medicine At Mount Sinai |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750626560 PECOS PAC ID: 2264691070 Enrollment ID: O20121218000412 |
News Archive
Bruker Corporation today announced the release of the Vutara VXL Super-Resolution Fluorescence Microscope for nanoscale biological imaging. The new system opens an affordable and easy-to-use path for both core facilities and individual investigators to enter the world of super-resolution imaging by incorporating Bruker's industry-leading single-molecule localization (SML) technology in a streamlined system with compact footprint.
Scientists at Cold Spring Harbor Laboratory (CSHL) and five other institutions have used an unconventional approach to cancer drug discovery to identify a new potential treatment for acute myeloid leukemia.
PLC Systems Inc., a company focused on innovative medical device technologies, today reported financial results for the three- and six month periods ended June 30, 2011. These results only include the company's RenalGuard® operations, since PLC completed the sale of its transmyocardial revascularization (TMR) business to Novadaq Corp. during the first quarter of 2011.
Clarient, Inc. has announced that it has been granted a new U.S. patent related to the detection and quantification of rare tumor cells in blood and bone marrow.
In a small study that included 25 patients with hereditary hemorrhagic telangiectasia (a genetic disorder that leads to abnormalities of blood vessels) and severe liver involvement with this disease, patients who received the drug bevacizumab had improved cardiac output and a reduction in the duration and number of episodes of nose bleeds, a potentially life-threatening complication for patients with this disorder, according to a study in the March 7 issue of JAMA.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Allison Weiss Langowski, AGPCNP-BC 223 N Van Dien Ave, Ridgewood, NJ 07450-2736 Ph: () - | Allison Weiss Langowski, AGPCNP-BC 223 N Van Dien Ave, Ridgewood, NJ 07450-2736 Ph: (201) 447-8000 |
News Archive
Bruker Corporation today announced the release of the Vutara VXL Super-Resolution Fluorescence Microscope for nanoscale biological imaging. The new system opens an affordable and easy-to-use path for both core facilities and individual investigators to enter the world of super-resolution imaging by incorporating Bruker's industry-leading single-molecule localization (SML) technology in a streamlined system with compact footprint.
Scientists at Cold Spring Harbor Laboratory (CSHL) and five other institutions have used an unconventional approach to cancer drug discovery to identify a new potential treatment for acute myeloid leukemia.
PLC Systems Inc., a company focused on innovative medical device technologies, today reported financial results for the three- and six month periods ended June 30, 2011. These results only include the company's RenalGuard® operations, since PLC completed the sale of its transmyocardial revascularization (TMR) business to Novadaq Corp. during the first quarter of 2011.
Clarient, Inc. has announced that it has been granted a new U.S. patent related to the detection and quantification of rare tumor cells in blood and bone marrow.
In a small study that included 25 patients with hereditary hemorrhagic telangiectasia (a genetic disorder that leads to abnormalities of blood vessels) and severe liver involvement with this disease, patients who received the drug bevacizumab had improved cardiac output and a reduction in the duration and number of episodes of nose bleeds, a potentially life-threatening complication for patients with this disorder, according to a study in the March 7 issue of JAMA.
› Verified 7 days ago
Jennifer Polizzano, APN-C Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 223 N Van Dien Ave, Ridgewood, NJ 07450 Phone: 201-447-8345 Fax: 201-447-8103 | |
Kelly Rumler, APN-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 223 N Van Dien Ave, Ridgewood, NJ 07450 Phone: 201-447-8000 | |
Samantha Leigh Guillod, APN Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 223 N Van Dien Ave, Ridgewood, NJ 07450 Phone: 201-447-8000 | |
Susan Bell, Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 505 Goffle Rd, Ridgewood, NJ 07450 Phone: 201-612-1006 Fax: 201-612-1091 | |
Kimberly Michele Pryslak, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 223 N Van Dien Ave, Ridgewood, NJ 07450 Phone: 201-447-8000 | |
Mary Catherine Collins, NURSE PRACTITIONER Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 223 N Van Dien Ave, Ridgewood, NJ 07450 Phone: 201-447-8371 | |
Mrs. Marianne Marie Longo, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1200 E Ridgewood Ave, 2nd Floor, Ridgewood, NJ 07450 Phone: 201-670-8660 Fax: 201-670-6693 |